- AstraZeneca India’s net income for the second quarter was 384.3 million rupees, marking a 27% decline compared to the same period last year.
- The company’s revenue showed a strong increase of 31% year-over-year, reaching 4.08 billion rupees.
- Total costs for the quarter rose by 39%, amounting to 3.65 billion rupees.
- Shares of AstraZeneca India fell by 2.8%, priced at 7,194 rupees, with 22,936 shares being traded.
- There were no recorded transactions of buys, holds, or sells for AstraZeneca India’s shares during this period.
- All comparisons to past results are based on the company’s original disclosures.
A look at AstraZeneca PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, AstraZeneca PLC presents a mixed outlook for investors. While the company performs relatively well in terms of growth and dividends, it lags in value, resilience, and momentum. With a growth score of 4, AstraZeneca demonstrates potential for expanding its operations and increasing its market share over the long term. Additionally, a dividend score of 3 indicates a moderate level of stability and income generation for investors. However, the company’s lower scores in value, resilience, and momentum suggest areas that may require attention for sustained performance.
AstraZeneca PLC, operating as a holding company, concentrates on pharmaceutical and medical product research, manufacturing, and sales. The company’s focus on various therapeutic areas, including gastrointestinal, oncology, cardiovascular, and respiratory, underpins its diverse product portfolio. Although AstraZeneca holds promise in terms of growth and dividend payouts, its overall outlook reflects a blend of opportunities and challenges that investors should consider when evaluating long-term investment strategies.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
